Manufacturer record
Marc Lifesciences Sikkim: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
11 batches manufactured by Marc Lifesciences Sikkim (Sikkim) were declared Not of Standard Quality between October 2025 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
11 records linked to Marc Lifesciences Sikkim in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Telmisartan Tablets IP 40mg | STS-114Mfg 2025-05 · Exp 2027-04 | DissolutionDissolution | Drugs Testing Laboratory, Chennai-06State lab | Jul 2026 |
| Telmisartan Tablets IP 40mg | STS-124Mfg 2025-06 · Exp 2027-05 | DissolutionDissolution | DTL, Chennai-06State lab | May 2026 |
| Telmisartan Tablets IP 40mg | STS-122Mfg 2025-06 · Exp 2027-05 | DissolutionDissolution | DTL,ChennaiState lab | Mar 2026 |
| Telmisartan Tablets IP 40mg | STS-119Mfg 2025-05 · Exp 2027-04 | DissolutionDissolution | DTL, Chennai-06State lab | Feb 2026 |
| Telmisartan Tablets IP 40mg | STS-123Mfg 2025-06 · Exp 2027-05 | Dissolution.Dissolution | DTL, Chennai-06State lab | Feb 2026 |
| Telmisartan Tablets IP 40mg | STS-126Mfg 2025-06 · Exp 2027-05 | DissolutionDissolution | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Telmisartan Tablets IP 40 mg | STS-117Mfg 2025-05 · Exp 2027-04 | DissolutionDissolution | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Glimpiride Tablets I.P. 2 MG. | SGYT-134Mfg 2025-03 · Exp 2027-02 | The sample does not conform to I.P. Standard with respect to descriptive Part of the Tablet.Other | State Drugs Testing Laboratory, Kolkata, West BengalState lab | Oct 2025 |
| Glimpiride Tablets I.P. 2 MG. | SGYT-120Mfg 2025-02 · Exp 2027-01 | The sample does not conform to I.P. Standard with respect to descriptive Part of the Tablet.Other | State Drugs Testing Laboratory, Kolkata, West BengalState lab | Oct 2025 |
| Glimpiride Tablets I.P. 2 MG. | SGYT-122Mfg 2025-02 · Exp 2027-01 | The sample does not conform to I.P. Standard with respect to descriptive Part of the Tablet.Other | State Drugs Testing Laboratory, Kolkata, West BengalState lab | Oct 2025 |
| Glimpiride Tablets I.P. 1 MG. | SLY-108Mfg 2024-09 · Exp 2026-08 | The sample does not conform to I.P. Standard with respect to descriptive Part of the Tablet.Other | State Drugs Testing Laboratory, Kolkata, West BengalState lab | Oct 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.